Williams G H, Hollenberg N K, Moore T J, Dluhy R G, Bavli S Z, Solomon H S, Mersey J H
Circ Res. 1978 Jan;42(1):46-52. doi: 10.1161/01.res.42.1.46.
Angiotensin II was infused at rates varying from 0.1 to 10 ng/kg per minute into 49 subjects with hypertension and 26 normotensive subjects and changes in blood pressure, plasma angiotensin II, and plasma renin activity (PRA) were determined after 20 and 30 minutes at each dose. Similar dose-related increases in angiotensin II and blood pressure occurred with a threshold of 1 ng/kg per minute in the normotensive and hypertensive subjects. Whereas angiotensin II induced a significant, dose-related decrement in renin activity in the normotensive subjects, with a threshold of 1.0 ng/kg per minute, no significant change in renin activity occurred in either the normal-renin or high-renin hypertensive subjects. In a separate study, nine normotensive and six hypertensive sodium-restricted subjects were given a converting enzyme inhibitor, SQ 20881, 30 microgram/kg. Despite a significantly greater fall in blood pressure (P less than 0.006) and angiotensin II concentration (P less than 0.045) in the hypertensive subjects, they did not have a greater rise in plasma renin activity. We conclude that angiotensin II reduces renin release in normal man at infusion rates that yield plasma angiotensin II levels within the physiological range but has a strikingly reduced influence on renin release in hypertension. In high-renin hypertension due to renal artery stenosis or nephrosclerosis, renin release is presumed to be relatively autonomous because of a dominant, intrarenal mechanism. The mechanism in normal-renin essential hypertension is not clear, but the abnormality could well be related to the pathogenesis of the hypertension.
以每分钟0.1至10纳克/千克的速率向49名高血压患者和26名血压正常的受试者输注血管紧张素II,并在每个剂量输注20分钟和30分钟后测定血压、血浆血管紧张素II和血浆肾素活性(PRA)的变化。在血压正常和高血压受试者中,血管紧张素II和血压出现了与剂量相关的类似升高,阈值为每分钟1纳克/千克。虽然血管紧张素II在血压正常的受试者中引起了肾素活性显著的、与剂量相关的降低,阈值为每分钟1.0纳克/千克,但正常肾素型或高肾素型高血压受试者的肾素活性均未发生显著变化。在另一项研究中,给9名血压正常和6名限制钠摄入的高血压受试者服用30微克/千克的转换酶抑制剂SQ 20881。尽管高血压受试者的血压(P<0.006)和血管紧张素II浓度下降幅度更大(P<0.045),但他们的血浆肾素活性升高幅度并不更大。我们得出结论,血管紧张素II在正常人体内以能使血浆血管紧张素II水平处于生理范围内的输注速率降低肾素释放,但对高血压患者肾素释放的影响显著降低。在因肾动脉狭窄或肾硬化导致的高肾素型高血压中,由于一种占主导地位的肾内机制,肾素释放被认为相对自主。正常肾素型原发性高血压的机制尚不清楚,但这种异常很可能与高血压的发病机制有关。